Literature DB >> 21541817

Myocardial perfusion PET: a split function?

Riemer H J A Slart.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21541817      PMCID: PMC3143320          DOI: 10.1007/s12350-011-9381-0

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


× No keyword cloud information.
Positron emission tomography (PET) plays an important role in the assessment of myocardial blood flow (MBF). Absolute quantification of MBF is feasible using tracer kinetic models.1 The most common method for quantifying MBF involves the acquisition of dynamic images with the cyclotron-produced radiopharmaceuticals 13N-ammonia and 15O-water. An alternative method is the use of the generator produced 82Rb. Several cardiovascular disorders have been evaluated with MBF PET. For instance, MBF measured by PET has been undertaken in patients with coronary artery disease (CAD), hypertrophic cardiomyopathy (HCM), idiopathic dilated cardiomyopathy (IDCM), and microvascular disease.2-5 Also, important long-term prognostic value of reduced coronary flow reserve in estimated with PET has been reported.5-7 In other words, MBF assessment provides a way to document and to estimate the risk of cardiovascular events. The majority of these previous studies are based on the MBF measurement of the entire myocardial wall. In this issue of the Journal of Nuclear Cardiology, Rutten-Vermeltfoort and colleagues present interesting data regarding the determination of subendocardial and subepicardial MBF in 27 healthy subjects assessed with 15O-labeled water.8 An additional MRI was performed to measure left ventricular volumes and function. They found that mean resting MBF in the subendocardium was higher than the subepicardium level. Of interest, during adenosine stress, vasodilation was augmented to a greater extent in the subepicardium compared with the subendocardium. The subendocardial-to-subepicardial MBF ratio decreased significantly during hyperemia (1.35 ± 0.23 to 1.12 ± 0.20, P < 0.001). Hyperemic transmural MBF was inversely correlated with left ventricular end-diastolic volume index (r 2 = 0.41, P = 0.0003), with a greater impact at the subendocardial level. The authors concluded that a transmural perfusion gradient can be detected in normal healthy subjects in a routine clinical setting with 15O-water PET. Evaluation of MBF in several cardiovascular disorders as mentioned previously can be optimized in a different way by applying a split up in subendocardial and subepicardial regions. As mentioned by the authors the transmural perfusion gradient can be determined in patients with hypertrophic hearts or in patients with cardiac syndrome X, for detecting microvascular dysfunction.4,9 For several reasons this study also offers opportunities for additional clinical applications, such as the unravelling of the etiology of transient ischemic dilatation (TID). An abnormal increase in TID ratio is regarded as an important marker that may indicate extensive CAD. It is described as an enlargement of the left ventricle (LV) cavity during stress due to extensive subendocardial ischemia that normalizes at rest. TID is frequently described as a combination of true physical dilatation of the end-diastolic volume, and apparent dilation caused by non-visualization of the sub-endocardium or by heart rate acceleration.10 Evaluation of subendocardial infarction is another field of interest. The method described in this study may assist in a better functional delineation of both layers of the myocardial wall. Up to now, MRI has played the leading role in the evaluation of subendothelial infarction. However, the anatomical and functional combination of PET-CT or even PET-MRI MBF with a contrast agent may replace the MRI approach. Absolute quantification of MBF is a strong tool of PET imaging, and the better delineation of the subendocardium by the current method in combination with CT may put PET-CT on a higher level. Further, one would suspect that cardiac resynchronization therapy (CRT) may affect the transmural flow gradient. If so, relating the subendocardium-to-subepicardium ratio to LV function may be used to evaluate or even predict the LV response on CRT. Finally, the quantification of regional myocardial blood flow may be clinically useful not only for assessing the extent and severity of CAD, but also to detect and measure impairments in microcirculatory function in non-coronary cardiac disease. The prognostic significance of transmural microcirculatory dysfunction in the absence of CAD however remains to be assessed. A number of technical aspects in this study need to be taken into account. As mentioned by the authors, tissue surrounding the myocardium could influence perfusion values and lead to heterogeneity of the perfusion pattern. Region definition of smaller areas of interest, such as with subendocardial and subepicardial flow measurements, will introduce more noise and potentially augment spillover artifacts from adjacent tissue. Moreover, spillover of activity between myocardial layers does occur. Simulation models and in vivo studies have revealed that the latter will result in underestimation of the transmural gradient. The limited spatial resolution remains an important drawback for accurate measurements (i.e., without bias) of subendocardial and subepicardial MBF using PET. In this study a PET scanner with moderate spatial resolution was used. In the last 2 decades, however, the spatial resolution of PET scanners has significantly improved (from >16 to <4 mm FWHM) and the impact of patient movement on quantification becomes more critical as the resolution increases. This is an area of active development and automated robust solutions for this long-standing issue should become available in the next years. It is also clear that resolution is not the only limiting factor. Cardiac and respiratory movements pose a limitation on the effective resolution achievable. Gating (list) mode using ECG and respiratory signal was lacking in this study and therefore poses a serious limitation. This will need to be applied in the future for optimal delineation of the subendocardial and subepicardial layers. Generator produced 82Rb for MBF estimation is of more general use in imaging centers, especially in USA. The positron range, however, of 82Rb is longer than 13N-ammonia and 15O-water and will result in suboptimal image resolution. Therefore, the determination of subendocardial and subepicardial MBF with 82Rb PET should be evaluated before it is applied clinically. Also, PET MBF protocols will differ between imaging centers, for instance the use of dynamic or static images. Static images have a higher (better) signal-to-noise ratio, but the subendocardial-to-subepicardial MBF ratio may be reduced due to redistribution of the tracer. On the other hand, will MBF modelling need to be redefined in dynamic imaging? Will the delineation of different borderzones influence regional perfusion results and should we thus redefine normal perfusion and MPR values? Previously, the determination of subendocardial and subepicardial MBF was validated mainly by animal experiments and microspheres.11 Of importance is the reproducibility of the transmural perfusion gradient, both test-re-test and between centers. This needs to be addressed in future studies. Finally, why only MBF for measurement in the subendocardium versus the subepicardium? Of interest may be metabolic imaging. FDG-PET, or even (neuro) receptor imaging might benefit from assessing transmural gradients. Myocardial ischemia and viability may also to be linked with metabolic12 and neuro-receptor gradient changes. In summary, the data of this study are encouraging. PET-(CT) MBF measurements may have additional clinical value using the transmural myocardial perfusion gradient. This “split function” method needs to be further optimized before optimal clinical utility.
  10 in total

1.  Myocardial perfusion quantification in patients suspected of cardiac syndrome X with positive and negative exercise testing: a [13N]ammonia positron emission tomography study.

Authors:  Jessica de Vries; Mike J L DeJongste; Gillian A J Jessurun; Pieter L Jager; Michiel J Staal; Riemer H J A Slart
Journal:  Nucl Med Commun       Date:  2006-10       Impact factor: 1.690

2.  Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging.

Authors:  G D Hutchins; M Schwaiger; K C Rosenspire; J Krivokapich; H Schelbert; D E Kuhl
Journal:  J Am Coll Cardiol       Date:  1990-04       Impact factor: 24.094

3.  Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve.

Authors:  Bernhard A Herzog; Lars Husmann; Ines Valenta; Oliver Gaemperli; Patrick T Siegrist; Fabian M Tay; Nina Burkhard; Christophe A Wyss; Philipp A Kaufmann
Journal:  J Am Coll Cardiol       Date:  2009-07-07       Impact factor: 24.094

4.  Dissociation of glucose tracer uptake and glucose transporter distribution in the regionally ischaemic isolated rat heart: application of a new autoradiographic technique.

Authors:  Richard Southworth; Jason L J Dearling; Rodolfo A Medina; Aiden A Flynn; R Barbara Pedley; Pamela B Garlick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-08-08       Impact factor: 9.236

5.  Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease.

Authors:  René A Tio; Ali Dabeshlim; Hans-Marc J Siebelink; Johan de Sutter; Hans L Hillege; Clark J Zeebregts; Rudi A J O Dierckx; Dirk J van Veldhuisen; Felix Zijlstra; Riemer H J A Slart
Journal:  J Nucl Med       Date:  2009-01-21       Impact factor: 10.057

6.  Transient ischemic dilatation ratio derived from myocardial perfusion scintigraphy: What are we looking at?

Authors:  B J van der Veen; N Kuperij; M P M Stokkel
Journal:  J Nucl Cardiol       Date:  2009-12-25       Impact factor: 5.952

Review 7.  Coronary microvascular dysfunction.

Authors:  Paolo G Camici; Filippo Crea
Journal:  N Engl J Med       Date:  2007-02-22       Impact factor: 91.245

8.  Ischemic patterns assessed by positron emission tomography predict adverse outcome in patients with idiopathic dilated cardiomyopathy.

Authors:  Richard M de Jong; Rene A Tio; Pim van der Harst; Adriaan A Voors; Paul M Koning; Clark J A M Zeebregts; Dirk J van Veldhuisen; Rudi A J O Dierckx; Riemer H J A Slart
Journal:  J Nucl Cardiol       Date:  2009-08-01       Impact factor: 5.952

9.  Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy.

Authors:  Paul Knaapen; Tjeerd Germans; Paolo G Camici; Ornella E Rimoldi; Folkert J ten Cate; Jurrien M ten Berg; Pieter A Dijkmans; Ronald Boellaard; Willem G van Dockum; Marco J W Götte; Jos W R Twisk; Albert C van Rossum; Adriaan A Lammertsma; Frans C Visser
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-12-21       Impact factor: 4.733

10.  Quantification of subendocardial and subepicardial blood flow using 15O-labeled water and PET: experimental validation.

Authors:  Ornella Rimoldi; Klaus P Schäfers; Ronald Boellaard; Federico Turkheimer; Lars Stegger; Marilyn P Law; Adriaan A Lammerstma; Paolo G Camici
Journal:  J Nucl Med       Date:  2006-01       Impact factor: 10.057

  10 in total
  1 in total

1.  Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy.

Authors:  Roberto Sciagrà; Alessandro Passeri; Fabrizio Cipollini; Helga Castagnoli; Iacopo Olivotto; Cyrill Burger; Franco Cecchi; Alberto Pupi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-27       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.